New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights